Oxandrolone 10mg/tab 100 Tabletten by Nassa Labs

Usage

1. Establish your peptide protocol first — confirm GHRP or GHRH dose, injection frequency, and IGF-1 baseline bloodwork before introducing Oxandrolone, so that any variable changes can be attributed accurately.
2. Begin Oxandrolone at 10 mg/day in week one of co-administration to assess individual tolerance before stepping to the target 20–30 mg/day range.
3. Align the first daily tablet with your primary morning GHRP injection to create overlapping androgenic and GH-axis stimulation during the highest-output training window.
4. Take the second daily tablet approximately six to eight hours after the first, timed to coincide with the afternoon peptide dose — avoid administering Oxandrolone within five hours of sleep to preserve nocturnal GH pulsatility.
5. Review IGF-1, fasting insulin, ALT/AST, and HDL cholesterol every four weeks; adjust Oxandrolone dose in single-tablet (10 mg) increments based on bloodwork and body-composition data.
6. Step Oxandrolone down by 10 mg per week from week nine onward while maintaining the peptide protocol; initiate PCT (SERM-based) approximately two days after the final Oxandrolone tablet, as plasma clearance occurs within approximately 48 hours of the last dose.

Warnings

Frequently asked questions

Which peptides are most commonly combined with Oxandrolone in a performance protocol?

GHRP-2, GHRP-6, and CJC-1295 without DAC are the most frequently used peptide companions to Oxandrolone. GHRP-class compounds stimulate pulsatile GH release via the ghrelin receptor, while Oxandrolone simultaneously occupies the androgen receptor to drive nitrogen retention — two non-competing pathways that together cover both the GH/IGF-1 axis and androgen-dependent lean-tissue preservation within a single protocol.

How should Oxandrolone dosing be timed around peptide injections for best results?

Administering the first daily Oxandrolone tablet in the morning aligns its plasma peak with the largest GHRP injection of the day, creating simultaneous androgenic and GH-axis stimulation during the training window. A second tablet taken six to eight hours later maintains steady androgen receptor occupancy through the afternoon peptide dose without competing with nocturnal GH pulsatility.

Does Oxandrolone interfere with the IGF-1 elevation produced by peptide protocols?

Oxandrolone does not suppress GH secretion or IGF-1 production; its mechanism is confined to androgen receptor engagement in peripheral tissues, leaving the hypothalamic-pituitary axis free to respond fully to GHRP and GHRH stimulation. The two compound classes therefore produce additive — not antagonistic — outcomes on lean body mass, as evidenced by body-composition data from clinical studies combining anabolic agents with GH-axis interventions.

Why is the 10 mg tablet strength particularly useful when running a peptide cycle?

Peptide protocols are typically titrated every two to four weeks based on IGF-1 bloodwork, requiring frequent dose recalibration of companion compounds. The 10 mg tablet unit allows single-step Oxandrolone adjustments in exact 10 mg increments, making it the lowest and most precise commercially available unit — essential when precision titration of every agent in a peptide stack is the goal.

Can the Nassa Labs Oxandrolone tablets be split for sub-10 mg dosing within a peptide protocol?

Splitting is physically possible but analytically inadvisable; tablet splitting distributes content unevenly and bypasses the content-uniformity guarantee that HPLC batch testing provides for intact 10 mg units. For sub-10 mg requirements — relevant mainly to female athletes in peptide-assisted protocols — a verified 5 mg alternative format is the safer choice; the 10 mg tablet is the precision floor for confirmed, uniform dosing. (2) angle_used

Manufacturer

Independent third-party analytical collaboration defines how Nassa Labs positions its oral tablet portfolio in a segment where declared content and actual content frequently diverge. For Oxandrolone 10mg/tab, the quality pathway routes each production batch through an external contract laboratory for HPLC content quantification and LAL endotoxin screening — neither test is conducted solely in-house, a deliberate structural choice that removes self-certification bias from the release decision. The resulting certificate, referenced by lot code, is held in a traceability register that authorised distribution partners can query against any specific order. This architecture reflects Nassa Labs' recognition that users building precision peptide protocols — where every compound dose must be verified before co-administration — require analytical evidence attached to the product, not merely a brand assurance attached to the label.